Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Qin, SK; Ren, ZG; Feng, YH; Yau, T; Wang, BC; Zhao, HT; Bai, YX; Gu, SZ; Li, LD; Hernandez, S; Xu, DZ; Mulla, S; Wang, YF; Shao, H; Cheng, AL

Cheng, AL (corresponding author), Natl Taiwan Univ Canc Ctr, Dept Med Oncol, Taipei, Taiwan.; Cheng, AL (corresponding author), Natl Taiwan Univ Hosp, Taipei, Taiwan.

LIVER CANCER, 2021; 10 (4): 296

Abstract

Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patie......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索